Total submissions: 1
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001951031 | SCV002238851 | pathogenic | Hermansky-Pudlak syndrome 2 | 2021-01-19 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Phe368Valfs*2) in the AP3B1 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in AP3B1 are known to be pathogenic (PMID: 16507770, 23403622). This variant is not present in population databases (ExAC no frequency). This variant has not been reported in the literature in individuals with AP3B1-related conditions. Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may create or strengthen a splice site, but this prediction has not been confirmed by published transcriptional studies. For these reasons, this variant has been classified as Pathogenic. |